submit to the journals

Chronic Lymphocytic Leukemia Journal Articles, Videos And Insights

Chronic Lymphocytic Leukemia:FEATURED Articles

flipper_slider

Chronic Lymphocytic Leukemia: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
The Prognostic Significance of TP-53 Clone Size in Relapsed/Refractory CLL Patients in the MURANO Study Katrina Mountfort
Senior Medical Writer, Touch Medical Media, UK

Chronic Lymphocytic Leukemia:FEATURED VIDEOS

Editor's choice

touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic lymphocytic leukaemia (CLL) patients with alterations in the TP53 pathway represent an unmet clinical need? (0:10) 2. Could you tell us a little about venetoclax and its efficacy in CLL? (1:11) 3. What is the safety profile of venetoclax? (2:05) 4. What was the rationale for the investigation of the impact of clone size on outcomes in patients in the MURANO study? (2:56) 5. What were the findings of this investigation and what are the implications of these findings? (4:29) Speaker disclosures: Arnon P Kater has nothing to disclose in relation to this video interview. Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018
Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma. 1. What are the most important unmet needs in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)? (0:11) 2. What do you consider the most promising treatments in clinical development for relapsed/refractory CLL? (0:51) 3. Can we predict in advance who is at high-risk to relapse and then modify therapy for these high-risk patients? (1:42) 4. What have been the most exciting recent developments in the treatment of diffuse large B-cell lymphoma (DLBCL)? (2:34) 5. What are the most exciting developments in the frontline treatment of follicular lymphoma? (3:26) Speaker disclosures: Ian W Flinn has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Chronic Lymphocytic Leukemia:Latest Videos

Video List based on Category on Node Page

Latest Videos

touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic...
Editorial board member, Ian W Flinn from Sarah Cannon, Tennesse Oncology, in Nashville, TN, talks to us about risk of relapse and promising treatments for relapsed/refractory CLL and advances in the treatment of DLBCL and follicular lymphoma. 1. What are the most important unmet needs...
Dr. John Pagel discusses the explosion of new treatment options for chronic lymphocytic leukemia (CLL). Learn more about new biological therapies.
Dr Campo (University of Barcelona, Barcelona, Spain) talks to ecancertv at EHA 2014 about the genetics of CLL, with specific reference to ibrutinib and the RESONATE trial.
Prof Robin Foa, Dr Simon Rule and Dr Clemens Wendtner discuss the main highlights presented from the ASH 2013 meeting.
Prof Gribben (Queen Mary University London, London, UK) chairs a discussion with Prof Hillmen (St James’ University Hospital, Leeds, UK), and Prof Mulligan (Royal North Shore Hospital, St Leonards, Australia) about the advances in CLL.

LATEST TWEETS

Conference Highlights